Evidence map›Paper›PMID 42518905›Full record

ArticleTurkish journal of chemistry2026

Production, purification, and crystallization of the recombinant HER2 tyrosine kinase domain (HER2-TKD).

Edanur Topalan, Halilibrahim Çiftçi, Hasan Demirci

Abstract read
In one paragraph

Article in Turkish journal of chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Edanur TopalanDepartment of Molecular Biology and Genetics, Faculty of Science, Koç University, İstanbul, Turkiye.ORCID https://orcid.org/0009-0009-0532-020X
Halilibrahim ÇiftçiMedicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID https://orcid.org/0000-0002-9796-7669
Hasan DemirciDepartment of Molecular Biology and Genetics, Faculty of Science, Koç University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-9135-5397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human epidermal growth factor receptor 2 tyrosine kinase domain (HER2-TKD) is an important therapeutic target in oncology. In this study, we developed a practical and cost-effective approach for producing soluble recombinant HER2-TKD in

Indexed as

Escherichia coliHER2-TKDinclusion bodiesprotein crystallizationsarcosylsoluble expression

Identifiers

PMID42518905
PMCPMC13384566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.